This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stock Market News for Nov 19, 2020
by Zacks Equity Research
Wall Street closed sharply lower on Wednesday on renewed threat of the latest surge in coronavirus infections.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
U.S. Crude Hits its Highest Price in 2 Months: Here's Why
by Nilanjan Choudhury
Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).
Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU
by Zacks Equity Research
Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.
Moderna's (MRNA) Coronavirus Vaccine Progress Hurts Pfizer
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine candidate seems to be more effective and its logistics less onerous than Pfizer and BioNTech's candidate.
Stock Market News for Nov 17, 2020
by Zacks Equity Research
Wall Street closed sharply higher on Monday buoyed by positive developments on coronavirus treatment front.
Energy Stocks Soar in Monday's Trading Session: Here's Why
by Nilanjan Choudhury
Energy was Monday's leading S&P sector performer with notable movers being TechnipFMC (FTI), Schlumberger (SLB), National Oilwell Varco (NOV) and Valero Energy (VLO).
Pfizer (PFE), BioNTech Fall After Moderna COVID-19 Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) stocks decline after Moderna COVID-19 vaccine candidate proves 94.5% effective and can be stored at standard refrigerator temperature.
5 Value Stocks to Benefit From Positive Vaccine News
by Zacks Equity Research
Positive vaccine news will help cyclical stocks make a comeback, making it judicious to invest in names like Vista Outdoor (VSTO) and Malibu Boats (MBUU).
3 Stocks to Win Big as Race for Coronavirus Vaccine Heats Up
by Tirthankar Chakraborty
Coronavirus vaccine race is now at its peak following Moderna's (MRNA) 94.5% effective vaccine in Phase 3 trials. Pfizer (PFE) also bragged about the effectiveness of its vaccine to be more than 90%.
Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks
by Nalak Das
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).
Markets Begin Pricing In Post-Pandemic Reality
by Mark Vickery
This is the second consecutive Monday where excellent news on Covid-19 vaccine potential got the trading week off on the right foot.
Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.
Positive Developments on COVID-19 Treatment Front
by Zacks Equity Research
Positive Developments on COVID-19 Treatment Front.
Moderna (MRNA) Covid Drug Proves 94.5% Efficacy
by Mark Vickery
The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.
J&J (JNJ) Expands BARDA Deal for COVID-19 Vaccine Development
by Zacks Equity Research
J&J's (JNJ) ENSEMBLE study on its COVID-19 vaccine candidate is expected to enroll 60,000 adult participants.
The S&P Hits a New High and the Dow Eyes Its Own 30K Milestone
by David Borun
Stocks continue to rally broadly on more good vaccine news, even as Covid-19 cases and deaths spike.
5 Stocks Poised to Soar on Strong Relative Price Strength
by Nilanjan Choudhury
Clean Harbors (CLH(, Harley-Davidson (HOG), Newell Brands (NWL), Regions Financial (RF) and Tapestry (TPR) are five stocks with explosive relative price strength.
This is Why Energy Stocks Suffered a Sharp Selloff Yesterday
by Nilanjan Choudhury
Following the surprise rise in crude stockpiles, some of the biggest casualties of the S&P 500 were energy-related names like Phillips 66 (PSX), Marathon Petroleum (MPC), Hess (HES), Valero Energy (VLO) and Occidental Petroleum (OXY).
Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress
by Zacks Equity Research
Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.
Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.
ETFs to Consider on Pfizer's Vaccine Announcement
by Sejuti Banerjea
ETFs with exposure to Pfizer (PFE) are beginning to look good after the results of BNT162b2's Phase 3 trial.
Biggest ETF Winners from Coronavirus Vaccine News
by Neena Mishra
Promising vaccine results from Pfizer sent economically sensitive stocks soaring
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Peloton Interactive, AMC Entertainment and Etsy
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Peloton Interactive, AMC Entertainment and Etsy